The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for ...

Jemperli’s was approved for the first-line ... a quick chat with the Grove.AI team about their new AI agent for clinical trial recruitment. AstraZeneca has become the first company to get ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

AnaptysBio discovered Jemperli, which was licensed to TESARO ... dedicated to conducting cooperative clinical trials. GSK Oncology, R&D global head and senior vice-president Hesham Abdullah ...

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

We're proud Jemperli continues to redefine the treatment ... including histologies often excluded from clinical trials and had approximately 10% of patients with carcinosarcoma and 20% with ...

Jemperli is a programmed death receptor-1 ... the standard of care in gynecologic oncology through cooperative clinical trials. GSK is a global biopharma company focused on uniting science ...

The approval broadens the previous indication for Jemperli plus chemotherapy in ... The company says RUBY Part 1 is the only clinical trial in this setting to show a clinically meaningful and ...